Cardiac amyloidosis: An update on diagnosis and treatment.

Authors:
Joseph P Donnelly
Joseph P Donnelly
Colorado State University
United States
Mazen Hanna
Mazen Hanna
Cleveland Clinic
Cleveland | United States

Cleve Clin J Med 2017 Dec;84(12 Suppl 3):12-26

Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA.

Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due to enhanced clinical awareness and better diagnostic imaging. CA is becoming of heightened interest to the cardiology community given more effective treatment strategies for light chain amyloidosis (AL), as well as emerging therapies for transthyretin amyloidosis (ATTR). Furthermore, reversing amyloid deposition in affected organs using monoclonal antibodies is actively being tested in clinical trials. A high index of suspicion and a systematic approach to the diagnosis of CA can lead to referral to a center of expertise for timely treatment.

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.84.s3.02DOI Listing
December 2017
9 Reads

Publication Analysis

Top Keywords

cardiac amyloidosis
8
amyloidosis attr
4
transthyretin amyloidosis
4
therapies transthyretin
4
attr reversing
4
reversing amyloid
4
deposition organs
4
amyloid deposition
4
emerging therapies
4
amyloidosis well
4
effective treatment
4
community effective
4
cardiology community
4
treatment strategies
4
strategies light
4
organs monoclonal
4
light chain
4
well emerging
4
monoclonal antibodies
4
lead referral
4

Similar Publications

Transthyretin Cardiac Amyloidosis in Older Americans.

J Card Fail 2016 Dec 18;22(12):996-1003. Epub 2016 Oct 18.

Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York. Electronic address:

Wild-type transthyretin cardiac amyloidosis (ATTRwt), formerly called senile cardiac amyloidosis (SCA), is almost exclusively a disorder of older adults. As the population ages, the diagnosis of ATTRwt will increase, making it the most common form of cardiac amyloidosis. An important precondition to reduce underdiagnosis and misdiagnosis is to maintain a high index of suspicion for cardiac amyloidosis. Read More

View Article
December 2016

Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy.

Clin Sci (Lond) 2017 Mar;131(5):395-409

Princess Margaret Cancer Centre, University Health Network, Department of Medical Biophysics, University of Toronto, TMDT 4-305, 101 College Street, Toronto, Ontario, Canada M5G 1L7

Transthyretin (TTR) amyloidosis (ATTR amyloidosis) is an underdiagnosed and important type of cardiomyopathy and/or polyneuropathy that requires increased awareness within the medical community. Raising awareness among clinicians about this type of neuropathy and lethal form of heart disease is critical for improving earlier diagnosis and the identification of patients for treatment. The following review summarizes current criteria used to diagnose both hereditary and wild-type ATTR (ATTRwt) amyloidosis, tools available to clinicians to improve diagnostic accuracy, available and newly developing therapeutics, as well as a brief biochemical and biophysical background of TTR amyloidogenesis. Read More

View Article
March 2017

Cardiac amyloidosis: updates in diagnosis and management.

Arch Cardiovasc Dis 2013 Oct 23;106(10):528-40. Epub 2013 Sep 23.

Service de cardiologie, pôle cœur-poumon-rein, hôpital Dupuytren, CHU de Limoges, 87042 Limoges, France; Service d'hématologie clinique et de thérapie cellulaire, pôle onco-hématologie, centre national de référence pour l'amylose AL et autres maladies de dépôts d'immunoglobulines monoclonales, CHU de Limoges, Limoges, France. Electronic address:

Amyloidosis is a severe systemic disease. Cardiac involvement may occur in the three main types of amyloidosis (acquired monoclonal light-chain, hereditary transthyretin and senile amyloidosis) and has a major impact on prognosis. Imaging the heart to characterize and detect early cardiac involvement is one of the major aims in the assessment of this disease. Read More

View Article
October 2013

CMR-based differentiation of AL and ATTR cardiac amyloidosis.

JACC Cardiovasc Imaging 2014 Feb 8;7(2):133-42. Epub 2014 Jan 8.

Cardiovascular Sciences, St. George's University of London, London, United Kingdom.

Objectives: This study was devised to describe the different cardiac magnetic resonance (CMR) appearances in light chain amyloid (AL) and transthyretin-related amyloidosis (ATTR).

Background: CMR is increasingly used to investigate patients with suspected amyloidosis. Global subendocardial late gadolinium enhancement (LGE) has been reported as typical of AL amyloidosis, whereas different patterns have been noted in ATTR amyloidosis. Read More

View Article
February 2014